J C Parker
Overview
Explore the profile of J C Parker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
350
Citations
3016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Corbett J, Dirico K, Song W, Boscoe B, Doran S, Boyer D, et al.
Bioorg Med Chem Lett
. 2007 Nov;
17(24):6707-13.
PMID: 17977724
The cis-3-amino-4-(2-cyanopyrrolidide)-pyrrolidine template has been shown to afford low nanomolar inhibitors of human DPP-IV that exhibit a robust PK/PD profile. An X-ray co-crystal structure of 5 confirmed the proposed mode...
12.
Parker J, Lavery K, Irwin N, Green B, Greer B, Harriott P, et al.
J Endocrinol
. 2006 Oct;
191(1):93-100.
PMID: 17065392
Glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are important enteroendocrine hormones that are rapidly degraded by an ubiquitous enzyme dipeptidyl peptidase IV to yield truncated metabolites GIP(3-42) and GLP-1(9-36)amide....
13.
Talwalkar S, Parker J, HEFFNER R, Parker J
Clin Neuropathol
. 2006 Jul;
25(4):180-4.
PMID: 16866299
Central core disease (CCD) is mainly a disease of infancy and childhood and represents a member of a group of muscular disorders known as "congenital, benign (non-progressive) myopathies". It is...
14.
Daviau J, Parker J, Parmelee R, Jahn S, Frank D
Contemp Top Lab Anim Sci
. 2006 Feb;
36(6):50-2.
PMID: 16450977
No abstract available.
15.
Yoshikawa S, King J, Lausch R, Penton A, Eyal F, Parker J
J Appl Physiol (1985)
. 2004 Nov;
97(6):2190-9.
PMID: 15531572
To determine the influence of experimental model and strain differences on the relationship of vascular permeability to inflammatory cytokine production after high peak inflation pressure (PIP) ventilation, we used isolated...
16.
Rhee S, Parker J, Smarr K, Petroski G, Johnson J, Hewett J, et al.
Arthritis Care Res
. 2003 Nov;
13(6):435-42.
PMID: 14635321
Objective: To test whether change in cognitive-behavioral variables (such as self-efficacy, coping strategies, and helplessness) is a mediator in the relation between cognitive behavior therapy and reduced pain and depression...
17.
Logan R, Nuttall R, Hazelwood S, Parker J, Johnson J, Hewett J, et al.
Arthritis Care Res
. 2003 Nov;
13(5):320-9.
PMID: 14635302
No abstract available.
18.
Gault V, Parker J, Harriott P, Flatt P, OHarte F
J Endocrinol
. 2002 Nov;
175(2):525-33.
PMID: 12429050
The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is rapidly degraded in the circulation by dipeptidyl peptidase IV forming the N-terminally truncated peptide GIP(3-42). The present study examined the biological activity...
19.
Parker J, Yoshikawa S
Am J Physiol Lung Cell Mol Physiol
. 2002 Oct;
283(6):L1203-9.
PMID: 12388351
The response of segmental filtration coefficients (Kf) to high peak inflation pressure (PIP) injury was determined in isolated perfused rat lungs. Total (K f,t ), arterial (K f,a ), and...
20.
OHarte F, Gault V, Parker J, Harriott P, Mooney M, Bailey C, et al.
Diabetologia
. 2002 Sep;
45(9):1281-91.
PMID: 12242461
Aims/hypothesis: This study examined the plasma stability, biological activity and antidiabetic potential of two novel N-terminally modified analogues of gastric inhibitory polypeptide (GIP). Methods: Degradation studies were carried out on...